- Previous Close
321.95 - Open
318.75 - Bid --
- Ask --
- Day's Range
316.05 - 324.95 - 52 Week Range
279.85 - 479.00 - Volume
18,446 - Avg. Volume
31,310 - Market Cap (intraday)
6.916B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
53.36 - EPS (TTM)
5.96 - Earnings Date Feb 8, 2025 - Feb 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
www.sakarhealthcare.com325
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SAKAR.NS
View MorePerformance Overview: SAKAR.NS
Trailing total returns as of 12/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SAKAR.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SAKAR.NS
View MoreValuation Measures
Market Cap
7.00B
Enterprise Value
7.74B
Trailing P/E
54.05
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.26
Price/Book (mrq)
2.60
Enterprise Value/Revenue
4.71
Enterprise Value/EBITDA
17.93
Financial Highlights
Profitability and Income Statement
Profit Margin
7.52%
Return on Assets (ttm)
3.90%
Return on Equity (ttm)
4.90%
Revenue (ttm)
1.65B
Net Income Avi to Common (ttm)
124.03M
Diluted EPS (ttm)
5.96
Balance Sheet and Cash Flow
Total Cash (mrq)
5.27M
Total Debt/Equity (mrq)
31.13%
Levered Free Cash Flow (ttm)
-418.3M